<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02080962</url>
  </required_header>
  <id_info>
    <org_study_id>399/2010</org_study_id>
    <nct_id>NCT02080962</nct_id>
  </id_info>
  <brief_title>Hypofractionated Radiotherapy for Nonmelanoma Skin Cancer</brief_title>
  <official_title>Hypofractionated Radiotherapy for Nonmelanoma Skin Cancer: Study Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barretos Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Barretos Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiotherapy is a treatment considered standard for non melanoma skin cancer. This&#xD;
      institution uses schemes of 4 to 6 weeks of treatment. The objective of the study is to&#xD;
      perform radiation therapy in 1 to 2 weeks, depending on the size of the lesion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Delineation of radiation field&#xD;
&#xD;
        -  Gross tumor volume (GTV): disease clinically visible / palpable&#xD;
&#xD;
        -  clinical target volume (CTV): equal to GTV&#xD;
&#xD;
        -  planned treatment volume (PTV):&#xD;
&#xD;
        -  tumors ≤ 2 cm in diameter, with 5-10 mm CTV margin&#xD;
&#xD;
        -  tumors&gt; 2-5 cm in diameter, with 15-20 mm CTV margin&#xD;
&#xD;
        -  Marking the GTV and PTV pen back projection&#xD;
&#xD;
        -  photograph of the treatment area&#xD;
&#xD;
        -  protections of the normal structures with blocks of lead, if necessary&#xD;
&#xD;
      Technical&#xD;
&#xD;
        -  Distance focus-skin Tube: 35 cm Locator: 30 and 40 cm&#xD;
&#xD;
        -  Sizes Tube: 2, 3 and 4 cm in diameter Finder: 6x8 cm, 8x10 cm&#xD;
&#xD;
        -  Energy:&#xD;
&#xD;
           80 kV 140 kv&#xD;
&#xD;
        -  Filter 80 kV, 2 mm Al 140 kv, 0.5 mm Copper&#xD;
&#xD;
        -  Current Draw: 20 mA&#xD;
&#xD;
      Dose&#xD;
&#xD;
        -  tumors ≤ 2 cm in diameter: 5 fractions of 600 cGy, once a day, five times a week - TDF:&#xD;
           89&#xD;
&#xD;
        -  tumors &gt; 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week -&#xD;
           TDF: 96&#xD;
&#xD;
      Clinical revisions every 5 weekly sessions, or a weekly and at the end of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low rate of recruitment.&#xD;
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of complete remission with hypofractionated RT schemes for NMSC.</measure>
    <time_frame>Second week and twelfth week after initiation of radiotherapy</time_frame>
    <description>RECIST criteria&#xD;
Complete Response: disappearance of the lesion&#xD;
Partial Response: Reduction ≥ 30% of the larger initial diameter of the lesion&#xD;
Progressive Disease: ≥ 20% increase in the largest initial diameter of the lesion&#xD;
Stable disease: not increase enough to consider disease progression or reduction sufficient to consider a partial response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Second week and twelfth week after initiation of radiotherapy</time_frame>
    <description>EORTC QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Second week and twelfth week after initiation of radiotherapy</time_frame>
    <description>Late Effects of Normal Tissue (LENT) SOMA Toxicity Grading and Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Non-melanoma Skin Cancer</condition>
  <arm_group>
    <arm_group_label>30 Gy in 5 fractions of 6 Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tumors ≤ 2 cm in diameter: 5 fractions of 600 cGy, once a day, five times a week - TDF: 89</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 Gy in 10 fractions of 4 Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tumors &gt; 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week - TDF: 96</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>30 Gy in 5 fractions</intervention_name>
    <description>5 fractions of 600 cGy, once a day, five times a week - TDF: 89</description>
    <arm_group_label>30 Gy in 5 fractions of 6 Gy</arm_group_label>
    <other_name>hypofractionated orthovoltage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>40 Gy in 10 fractions</intervention_name>
    <description>tumors &gt; 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week - TDF: 96</description>
    <arm_group_label>40 Gy in 10 fractions of 4 Gy</arm_group_label>
    <other_name>hypofractionated orthovoltage</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cosmesis not important&#xD;
&#xD;
          -  Basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) of any differentiation&#xD;
&#xD;
          -  Clinical stage I and II&#xD;
&#xD;
          -  Location on the thorax, abdomen, pelvis (except perineum), arm, thigh, cheek&#xD;
&#xD;
          -  Patient with up to 3 injuries eligible for the study&#xD;
&#xD;
          -  Karnofsky Performance Status (KPS) ≥ 70%&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Informed Consent signed by the patient consenting to undergo the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Indian Race&#xD;
&#xD;
          -  Prior treatment for their skin cancer&#xD;
&#xD;
          -  More than three synchronous lesions to treatment with RT&#xD;
&#xD;
          -  Basal syndrome, xeroderma, vitiligo and albinism&#xD;
&#xD;
          -  Immunosuppression&#xD;
&#xD;
          -  Prior burn at the tumor site&#xD;
&#xD;
          -  Tumor &gt; 5 cm&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Carrier mental incapacity&#xD;
&#xD;
          -  People in a relationship of dependence as prisoners, soldiers, students, staff, etc..&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo A Nakamura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barretos Cancer Hospital - Fundação Pio XII</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barretos Cancer Hospital - Fundacao Pio XII</name>
      <address>
        <city>Barretos</city>
        <state>Sao Paulo</state>
        <zip>14784400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>February 3, 2014</study_first_submitted>
  <study_first_submitted_qc>March 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2014</study_first_posted>
  <last_update_submitted>March 5, 2014</last_update_submitted>
  <last_update_submitted_qc>March 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-melanoma skin cancer, radiotherapy, orthovoltage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

